Study: PA Biotech Center of Bucks County Spurs $1.8 Billion in Economic ImpactNew Page
Companies located at the Pennsylvania Biotechnology Center have created 325 direct and 402 indirect jobs
DOYLESTOWN, Pa. (March 2016) – Over the past three years, the Pennsylvania Biotechnology Center of Bucks County has created 727 jobs and has spurred more than $1.8 billion in economic impact in Bucks County and throughout Pennsylvania, according to an economic impact study released March 8.
Commissioned by the Baruch S. Blumberg Institute, the report by KLIOS Consulting LLC, uses the Regional Input-Output Modeling System (RIMS II) developed by the U.S. Department of Commerce, to measure direct, indirect and induced economic impacts.
“This study demonstrates a doubling of dollar value of economic impact from the PA Biotech Center since the last study was performed in 2012,” said study leader economist Richard Stein. “The PA Biotech Center continues to yield significant benefits to the region and the Commonwealth.”
A nonprofit organization founded specifically to foster business and job growth, the PA Biotech Center has created $1.6 billion in economic impact in Bucks County and another $227 million in economic impact to the Commonwealth of Pennsylvania. That breaks down to:
• $593 million in direct impact
• $837 million in indirect impact
• $373 million in induced impact
In addition, the center has created 325 jobs directly associated with the center, 237 additional indirect jobs in Bucks County and 165 jobs elsewhere in Pennsylvania.
Pennsylvania state Sen. Chuck McIlhinney, an early and strong proponent of the center, notes, “The Pennsylvania Biotechnology Center and the Blumberg Institute clearly have exceeded all expectations in creating jobs, fostering entrepreneurship, and bringing hope to so many people suffering from human disease. Given their track record, I can see this is just the beginning, and that Bucks County will continue to evolve into a major center for biotechnology entrepreneurship.”
Created in 2006 by the Hepatitis B Foundation in partnership with Delaware Valley College (now University), the PA Biotech Center converted an abandoned light industrial site north of Doylestown into a state-of-the art biotech center and pledged to replace the 145 jobs lost when the site’s former occupant, the D. A. Lewis Associates Inc. fulfillment center, closed. As the report by Stein demonstrates, in addition to being home to the Hepatitis B Foundation and its nonprofit research institution, the Baruch S. Blumberg Institute, which manages the center, the PA Biotech Center now is home to more than 35 start-up companies.
“The Baruch S. Blumberg Institute and the PA Biotech Center continue to be a source of pride to this community, turning ideas and dreams into innovations, medicines, and, importantly, jobs,” said Pennsylvania state Rep. Marguerite Quinn, another early supporter of the center.
The PA Biotechnology Center employs an unusual model in which an anchor, nonprofit organization dedicated to drug and diagnostics discovery for liver disease, actively spins out and attracts new companies and entrepreneurs. “That approach is working,” said the center’s Chief Operating Officer Lou Kassa.
Many biotech incubators fall short on delivering their promises of helping spur new companies and create reliable jobs, according to a 2015 Kauffman Foundation study. Indeed, most technology accelerators fail, writes Peter Relan, venture capitalist and founder of YouWeb, writing in Technology Link.
“The PA Biotech Center has fostered some extraordinary success stories in the past few years, and those companies now are models and inspiration for the newer start-ups here,” notes Dr. Timothy Block, president and co-founder of the Biotech Center and president of the Hepatitis B Foundation and the Baruch S. Blumberg Institute. ”The PA Biotech Center has on site some of the most accomplished drug discovery scientists and entrepreneurs in the world.”
In addition to the economic impact documented in this study, the start-up companies located at the PA Biotech Center now are valued at more than $1.2 billion. Some of the success stories include:
Michael Sofia, Ph.D., co-inventor of the hepatitis C cure sofusbovir (Sovaldi), started a company at the PA Biotech Center to discover a cure for hepatitis B, using technology discovered and licensed by the Blumberg Institute. Now called Arbutus Biopharma, the company is valued at more than $500 million.
The research division for Synergy Pharmaceuticals, a publicly traded company worth more than $1.2 billion, also is located at the PA Biotech Center. Kunwar Shailubhai, Ph.D., executive vice president and chief scientific officer of Synergy, recently celebrated New Drug Application approval for Synergy’s pipeline drug plecanatide, which treats gastrointestinal distress.
Novira Therapeutics, which was founded to focus on a cure for hepatitis B, recently was acquired by Johnson & Johnson for an undisclosed amount of money. Novira has a hepatitis B drug in human studies.
“The PA Biotech Center has been a tremendous success, and with more space for expansion, we could do even more,” said Kassa. “This is just the beginning.”